Insider Selling: Shoulder Innovations (NYSE:SI) Major Shareholder Sells $2,272,719.24 in Stock

Shoulder Innovations, Inc. (NYSE:SI) major shareholder Healthcare Holding B.V. Gilde sold 99,812 shares of Shoulder Innovations stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $22.77, for a total transaction of $2,272,719.24. Following the sale, the insider owned 2,221,640 shares of the company’s stock, valued at approximately $50,586,742.80. The trade was a 4.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Healthcare Holding B.V. Gilde also recently made the following trade(s):

• On Thursday, August 6th, Healthcare Holding B.V. Gilde sold 2,095 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.60, for a total transaction of $47,347.00.
• On Wednesday, August 5th, Healthcare Holding B.V. Gilde sold 7,338 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.64, for a total transaction of $166,132.32.
• On Monday, August 3rd, Healthcare Holding B.V. Gilde sold 10,751 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.71, for a total transaction of $244,155.21.
• On Friday, July 31st, Healthcare Holding B.V. Gilde sold 20,034 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.73, for a total value of $455,372.82.
• On Thursday, July 30th, Healthcare Holding B.V. Gilde sold 28,245 shares of Shoulder Innovations stock. The shares were sold at an average price of $23.36, for a total value of $659,803.20.

Shoulder Innovations Stock Performance

Shares of SI stock opened at $20.54 on Friday. Shoulder Innovations, Inc. has a 52-week low of $10.92 and a 52-week high of $24.59. The company has a quick ratio of 10.04, a current ratio of 11.81 and a debt-to-equity ratio of 0.11. The stock has a market cap of $426.06 million and a PE ratio of -10.70. The business has a 50-day simple moving average of $19.91 and a 200-day simple moving average of $16.07.

Shoulder Innovations (NYSE:SI) last posted its earnings results on Wednesday, May 13th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.03. Shoulder Innovations had a negative return on equity of 22.93% and a negative net margin of 58.33%.The firm had revenue of $16.71 million for the quarter. On average, equities analysts expect that Shoulder Innovations, Inc. will post -1.67 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Weiss Ratings upgraded shares of Shoulder Innovations from a “sell (d-)” rating to a “sell (d)” rating in a research note on Monday. UBS Group started coverage on shares of Shoulder Innovations in a research report on Tuesday, July 28th. They set a “buy” rating and a $27.00 price target on the stock. Piper Sandler reiterated an “overweight” rating and issued a $25.00 price objective (up from $19.00) on shares of Shoulder Innovations in a research report on Friday. Finally, BTIG Research increased their target price on shares of Shoulder Innovations from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $23.33.

Key Headlines Impacting Shoulder Innovations

Here are the key news stories impacting Shoulder Innovations this week:

• Positive Sentiment: Analysts raised their targets: Piper Sandler reaffirmed its “overweight” rating and lifted its price target from $19 to $25, while BTIG Research raised its target from $24 to $26 and initiated a “buy” rating. These targets imply meaningful upside and may support investor sentiment. Benzinga analyst rating updates
• Positive Sentiment: Revenue growth remained strong: Second-quarter revenue increased approximately 56% year over year to $17.2 million, slightly exceeding estimates. Gross profit rose about 60%, indicating continued demand and improving product economics. Shoulder Innovations Q2 2026 earnings summary
• Positive Sentiment: Full-year guidance was raised: SI forecast fiscal-year revenue of $67 million to $69 million, broadly in line with the roughly $67.1 million consensus estimate. Management also highlighted 60% first-half revenue growth. Shoulder Innovations raises full-year outlook
• Neutral Sentiment: Liquidity appears adequate but is declining: The company ended the quarter with $24.5 million in cash and used $7.4 million in operating activities and $2.2 million in capital expenditures. Investors will likely monitor whether revenue growth can lead to improved cash generation.
• Negative Sentiment: Profitability remains a concern: SI reported an operating loss of about $10 million, a net loss of approximately $10.2 million, and diluted EPS near negative $0.49, missing some estimates. The company remains deeply unprofitable, increasing valuation sensitivity. Shoulder Innovations quarterly results
• Negative Sentiment: Major-holder selling may weigh on sentiment: Gilde Healthcare sold more than 110,000 shares in early August for roughly $2.5 million. Although it retains a substantial stake, the sales can raise concerns about near-term supply and insider conviction. Gilde Healthcare insider sale

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Sectoral Asset Management Inc. increased its holdings in Shoulder Innovations by 14.4% in the 4th quarter. Sectoral Asset Management Inc. now owns 492,435 shares of the company’s stock worth $7,042,000 after acquiring an additional 62,153 shares in the last quarter. Deerfield Management Company L.P. purchased a new position in Shoulder Innovations during the third quarter valued at $6,056,000. Alyeska Investment Group L.P. purchased a new position in Shoulder Innovations during the third quarter valued at $5,667,000. Roubaix Capital LLC grew its position in shares of Shoulder Innovations by 61.9% in the first quarter. Roubaix Capital LLC now owns 257,121 shares of the company’s stock valued at $3,736,000 after purchasing an additional 98,305 shares during the period. Finally, Vanguard Group Inc. acquired a new stake in shares of Shoulder Innovations in the third quarter valued at about $1,836,000.

About Shoulder Innovations

Shoulder Innovations (NYSE:SI) is a medical device company focused on the design, development and commercialization of shoulder implant systems and related surgical instruments for orthopedic surgery. The company’s product portfolio includes modular shoulder prostheses, humeral and glenoid components, and instrumentation kits designed to facilitate both primary and revision shoulder arthroplasty procedures. Emphasizing a patient-centric approach, Shoulder Innovations works to offer implant solutions that aim to restore mobility and reduce post-operative complications.

In addition to its core implant offerings, Shoulder Innovations provides comprehensive clinical support and training programs for surgeons and operating room teams.